Page 47 - Demo

3Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohortsubmitted Annette A. van Zweeden, MD1,2, Lydia.G.M. van der Geest, PhD1,3, Esther N. Pijnappel, MD, PhD1, Judith de Vos-Geelen, MD, PhD, assistant professor4, Jeanin E. van Hooft, MD, PhD, professor5, Martijn W.J. Stommel MD, PhD6, Gijs F. de Wit, MD7, Henk M.W. Verheul, MD, PhD, professor8, Hanneke W.M. van Laarhoven, MD, PhD, professor1,9, Hans J. van der Vliet, MD, PhD, professor1 ,9, 10 and Johanna W. Wilmink, MD, PhD, professor1,9* on behalf of the Dutch Pancreatic Cancer Group1 Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands 2 Amstelland Hospital, Department of Internal Medicine, Amstelveen, The Netherlands 3 Netherlands Comprehensive Cancer Organization (IKNL), Department of Research and Development, Utrecht, The Netherlands 4 Div. Medical Oncology, Dept. Internal Medicine, GROW, Maastricht University Medical Centre, Maastricht, The Netherlands 5 Leiden University Medical Center, Department of Gastroenterology and Hepatology, The Netherlands 6 Radboud University Medical Center, Department of Surgery, Nijmegen, the Netherlands 7 Tergooi Hospitals, Department of Internal Medicine, Hilversum, The Netherlands 8 Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands 9 Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands 10 Lava Therapeutics, Utrecht, The Netherlands*Corresponding author